Back to Agenda
Interpretation of New Pharmacovigilance Regulations: Key Insights
Session Chair(s)
Ajay B. Singh
Team Leader, Safety Evaluation and Risk Management, GlaxoSmithKline, United States
Building on the ongoing collaborative efforts of nineteen sponsor companies, a key workstream has been established on how each is addressing major new pharmacovigilance regulations and guidances. This session will provide feedback on key learnings and best practices. Join the Clinical Safety & Pharmacovigilance Community for a follow up Round Table discussion on Tuesday, June 25, 9:30-10:30AM in the DIA Community Zone 1, Sails Pavilion.
Learning Objective : Explain some of the challenges associated with major new pharmacovigilance guidelines; Discuss how companies are interpreting and implementing the aforementioned guidelines; Share best practices across the industry and learnings from feedback from regulators.
Speaker(s)
Ajay B. Singh
Team Leader, Safety Evaluation and Risk Management, GlaxoSmithKline, United States
Reference Satety Information: Implementing the Recommendations Noted in the CTFG
Mick Foy
Director of Delivery, Medicines and Healthcare Products Regulatory Agency (MHRA), United Kingdom
Update From MHRA
Jane Carroll, BSN, MS, RN
Vice President, Commercial and Medical Operations, Moderna, United States
Combination Products: Focus on FDA Guidance on Postmarketing Safety Reporting
Have an account?